as a clinical-stage pharmaceutical company founded on cutting-edge research, essa is focused on developing novel therapeutics for cancer patients. essa embraces innovation not only in our products but also in our approach. we're firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.
Company profile
Ticker
EPIX
Exchange
Website
CEO
David R. Parkinson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ESSA Pharmaceuticals Corp. ...
EPIX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
5 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
7 Mar 24
10-Q
2024 Q1
Quarterly report
13 Feb 24
8-K
Results of Operations and Financial Condition
13 Feb 24
8-K
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
29 Jan 24
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEF 14A
Definitive proxy
26 Jan 24
8-K
Results of Operations and Financial Condition
12 Dec 23
10-K
2023 FY
Annual report
12 Dec 23
8-K
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
6 Nov 23
Latest ownership filings
4
Peter Virsik
5 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
4
SANFORD S ZWEIFACH
28 Mar 24
4
Marella Thorell
28 Mar 24
4
Gary Sollis
28 Mar 24
4
Scott Requadt
28 Mar 24
4
Lauren Merendino
28 Mar 24
4
John Alexander Martin
28 Mar 24
4
Philip W. Kantoff
28 Mar 24
4
Richard M Glickman
28 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.70 mm | 33.70 mm | 33.70 mm | 33.70 mm | 33.70 mm | 33.70 mm |
Cash burn (monthly) | 1.59 mm | 1.95 mm | 1.83 mm | 2.22 mm | 1.50 mm | 1.65 mm |
Cash used (since last report) | 10.88 mm | 13.35 mm | 12.52 mm | 15.18 mm | 10.25 mm | 11.29 mm |
Cash remaining | 22.82 mm | 20.36 mm | 21.18 mm | 18.52 mm | 23.45 mm | 22.41 mm |
Runway (months of cash) | 14.4 | 10.5 | 11.6 | 8.4 | 15.7 | 13.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 5 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 89.04 bn |
Total shares | 58.85 mm |
Total puts | 26.40 k |
Total calls | 15.90 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 8.75 mm | $23.53 mm |
BVF | 8.75 mm | $23.62 bn |
BLVGF Bellevue | 7.90 mm | $21.33 bn |
BBBOF BB Biotech | 7.88 mm | $0.00 |
Partner Fund Management | 4.20 mm | $11.35 bn |
Soleus Capital Management | 4.20 mm | $11.35 bn |
MS Morgan Stanley | 3.87 mm | $10.45 bn |
Soleus Capital | 3.87 mm | $0.00 |
Clarus Lifesciences III | 2.19 mm | $26.71 mm |
PFE Pfizer | 1.68 mm | $23.79 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Peter Virsik | Common Shares | Sell | Dispose S | No | Yes | 7.94 | 694 | 5.51 k | 11,940 |
25 Mar 24 | Sanford S Zweifach | Options Common Shares | Grant | Acquire A | No | No | 9.04 | 50,000 | 452.00 k | 50,000 |
25 Mar 24 | Marella Thorell | Options Common Shares | Grant | Acquire A | No | No | 9.04 | 50,000 | 452.00 k | 50,000 |
25 Mar 24 | Gary Sollis | Options Common Shares | Grant | Acquire A | No | No | 9.04 | 50,000 | 452.00 k | 50,000 |
25 Mar 24 | Scott Requadt | Options Common Shares | Grant | Acquire A | No | No | 9.04 | 50,000 | 452.00 k | 50,000 |
News
ESSA Pharma: Q1 Earnings Insights
13 Feb 24
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
30 Jan 24
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
26 Jan 24
What's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?
26 Jan 24
Press releases
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
9 Apr 24
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
7 Mar 24
Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?
16 Feb 24
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
13 Feb 24
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
6 Feb 24